Today - at this point in time - we can take this step in regenerative medicine to influence the future of mankind.—Chuck Hull, co-founder of 3D Systems and inventor of 3D printing
For more than three decades, 3D Systems created new approaches and processes for product development, parts manufacturing and personalized healthcare through additive manufacturing solutions.
Now, we are leveraging this experience to innovate bioprinting technologies to transform patient care. By enabling the fabrication of living tissues, bioprinting is pushing the limits of regenerative medicine that will disrupt healthcare as we know it.
Learn how the 3D Systems bioprinting portfolio will unlock the promise and potential of regenerative medicine below:
Research and Development
The research community is critical to developing breakthrough innovations in regenerative medicine. 3D Systems, with the addition of Allevi Inc in May 2021, provides a robust set of bioprinting solutions to researchers and industry giants in hundreds of labs globally. Allevi is a leading innovator in the bioprinting space with exclusive focus on the research and development community. Leading laboratories leverage Allevi’s portfolio of hardware, biomaterials and software to design, engineer and build solutions for tissue engineering, organ-on-a-chip research, pharmaceutical validation, biomaterial development, and regenerative medicine.
Allevi desktop 3D bioprinters are the most versatile, powerful and easy-to-use bioprinters on the market. Customers also have access to a wide range of biomaterials—bioinks, bioink additives, cells, reagents and consumables—as well as an intuitive software interface.
3D Systems has delivered additive manufacturing solutions to the healthcare community for more than 30 years. Having produced more than 2,000,000 serial component medical devices and 140,000 patient specific surgical cases, we are eager to bring this experience to scaling production of bioprinted clinical applications. Our technology will elevate patient care through various clinical applications ranging from acellular bioresorbable devices to functionalized solid organs for transplantation.
Together with United Therapeutics Corporation and its organ manufacturing and transplantation-focused subsidiary, Lung Biotechnology PBC, we achieved significant progress in the development of next generation bioprinting solutions for lung scaffolds that are capable of full size, vascularized, rapid, micron-level printing.
3D Systems’ capabilities as a technology innovator, spanning hardware, software, and materials science, combined with United Therapeutics’ renowned expertise in regenerative medicine has enabled advances in lung modeling, 3D printing, as well as material formulation and material handling to yield significant capabilities in bioprinters and biomaterials for the eventual production of transplantable organs.
Read more about the United Therapeutics organ manufacturing platform.
Advanced Bioprinting Technology Development
To meet the evolving needs of the clinical and R&D communities, we continue to push our technologies to facilitate advanced application development. Our Print to Perfusion™ process enables 3D printing of high-resolution scaffolds, which can be perfused with living cells to create tissues.
The ability to print large, vascularized, highly detailed hydrogel scaffolds at rapid speeds is opening new opportunities for a range of tissue applications. In addition, we are developing bioprinting solutions that are both commercially viable and scalable from prototype to production.
Read CEO Jeff Graves and CTO and co-founder Chuck Hull’s perspectives on bioprinting in Forbes.
Complex Biological Structures and Tissue Engineering
The acquisition of Volumetric Biotechnologies brings exceptional tissue engineering and biological expertise to expand the scope of human organ bioprinting efforts at 3D Systems.
We are establishing a world-class research facility in Houston, Texas to accelerate the development and commercialization of vascularized human tissues and bioprinted constructs for non-organ applications, and creating clear technological leadership in the rapidly emerging bioprinting field for laboratory applications including drug discovery.
Growing Regenerative Medicine and Bioprinting Solutions through Partnership
We believe in growing the industry together through partnerships. Our existing collaborations with CollPlant Biotechnologies and Antleron expand the capabilities in regenerative medicine research and development solutions.
In addition, we continue to seek partners with the same mission of transforming healthcare through groundbreaking technologies.